Literature DB >> 30114933

TEG-seq: an ion torrent-adapted NGS workflow for in cellulo mapping of CRISPR specificity.

Pei-Zhong Tang1, Bo Ding1, Lansha Peng1, Vadim Mozhayskiy1, Jason Potter1, Jonathan D Chesnut1.   

Abstract

GUIDE-seq was developed to detect CRISPR/Cas9 off-target. However, as originally reported, it was associated with a high level of nonspecific amplification. In an attempt to improve it, we developed target-enriched GUIDE-seq (TEG-seq). The sensitivity level reached 0.1-10 reads-per-million  depending on the NGS platform used, which was equivalent to 0.0002-1% measured by Targeted Amplicon-seq. Application of TEG-seq was demonstrated for the evaluation of various Cas9/gRNA configurations, which suggests delivery of Cas9/gRNA ribonucleoprotein results in significantly fewer off-targets than Cas9/gRNA plasmid. TEG-seq was also applied to 22 gRNAs with relatively high in silico ranking score that targeted the biological relevant SNPs. The result indicated the initial selection of gRNAs with high score is important, although it cannot exclude the possibility of off-target.

Keywords:  CRISPR/cas9; GUIDE-seq; TEG-seq; gene editing; off-target

Mesh:

Substances:

Year:  2018        PMID: 30114933     DOI: 10.2144/btn-2018-0105

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  3 in total

1.  Rational Engineering of CRISPR-Cas9 Nuclease to Attenuate Position-Dependent Off-Target Effects.

Authors:  Zhicheng Zuo; Kesavan Babu; Chhandosee Ganguly; Ashwini Zolekar; Sydney Newsom; Rakhi Rajan; Yu-Chieh Wang; Jin Liu
Journal:  CRISPR J       Date:  2022-04

2.  CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.

Authors:  Patrick Hwu; Chantale Bernatchez; Amir A Jazaeri; Samantha M Fix; Marie-Andrée Forget; Donastas Sakellariou-Thompson; Yunfei Wang; Tamara M Griffiths; Minjung Lee; Cara L Haymaker; Ana Lucía Dominguez; Rafet Basar; Christopher Reyes; Sanjay Kumar; Larissa A Meyer
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

Review 3.  mRNA and gene editing: Late breaking therapies in liver diseases.

Authors:  Nerea Zabaleta; Laura Torella; Nicholas D Weber; Gloria Gonzalez-Aseguinolaza
Journal:  Hepatology       Date:  2022-04-01       Impact factor: 17.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.